TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14747042
Drug: Estramustine (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estramustine (280 mg tid, days 1 to 5) and docetaxel (70 mg/m2 on day 2) before radical prostatectomy (RP)
Study: 10718464
Drug: Antireflux therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antireflux therapy (nizatidine)
Study: 9177894
Drug: Trypsin: chymotrypsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trypsin: chymotrypsin (Chymoral forte DS) preparation
Study: 8263885
Drug: Hydroflumethiazide 50
Normalized name: hydroflumethiazide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroflumethiazide 50 mg and Reserpine 0.125 mg (H-R)
Study: 8263885
Drug: Chlortalidone 12.5
Normalized name: Atenolol 50 mg and chlortalidone 12.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortalidone 12.5 mg and Atenolol 50 mg (C-A)
Study: 2939815
Drug: Subcutaneous catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous catheter irrigated with antibiotic
Study: 2939815
Drug: Subcutaneous catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous catheter irrigated with saline
Study: 2939815
Drug: Subcutaneous catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous catheter alone
Study: 31780023
Drug: Oil pulling
Normalized name: JASMINUM SAMBAC WHOLE 0.119 g in 119 g / ORIGANUM VULGARE LEAF OIL 0.119 g in 119 g / FOENICULUM VULGARE (FENNEL) SEED EXTRACT 0.119 g in 119 g / MENTHA VIRIDIS (SPEARMINT) LEAF OIL 0.119 g in 119 g / ALPINIA KATSUMADAI SEED EXTRACT 0.119 g in 119 g ORAL PASTE [YOUBUY post oil pulling tooth-paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil pulling therapy with coconut oil
Study: 29920852
Drug: Morphine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1.5 mg
Study: 29920852
Drug: Morphine in
Normalized name: morphine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine in trapezius muscle
Study: 25166443
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (Aqua Touch™) applied immediately before cystoscopy (Group 2)
Study: 25166443
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (Aqua Touch™) applied with a 10-minute clamping before cystoscopy (Group 3)
Study: 19666195
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy + Treatment As Usual (MBCT+TAU)
Study: 16202291
Drug: 3 day
Normalized name: Kathro 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 day miconazole (400 mg/d)
Study: 16202291
Drug: 6 day
Normalized name: Kathro 6 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 day miconazole (400 mg/d)
Study: 16202291
Drug: 7 day
Normalized name: ZonaCort 7 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day miconazole (200 mg/d)
Study: 12891550
Drug: Regular milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular milk products (calcium supply, 1100 mg/day)
Study: 12891550
Drug: Placebo milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo milk products (calcium supply, 60 mg/day)
Study: 1831628
Drug: Ondansetron plus
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron plus dexamethasone (ondansetron 0.15 mg/kg IV every 2 hours + dexamethasone 20 mg IV single dose)
Study: 1831628
Drug: Ondansetron alone
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron alone (ondansetron 0.15 mg/kg IV every 2 hours)
Study: 25649640
Drug: Avizor Alvera®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avizor Alvera® (study solution)
Study: 25649640
Drug: All Clean
Normalized name: Water, Sea Otic Solution [ALL CLEAN EAR CLEANSING SYSTEM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All Clean Soft® (control solution)
Study: 24819510
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH) along with physical measures (compression stockings)
Study: 21849647
Drug: Interferon β‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon β‐1b (250 μg, subcutaneously every other day for 2 years)
Study: 22227558
Drug: risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone 6 mg/day
Study: 22227558
Drug: haloperidol 20
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol 20 mg/day
Study: 19139851
Drug: Medication-free SCH
Normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free SCH patients
Study: 17456248
Drug: Multivitamin tablets
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multivitamin tablets (n 28)
Study: 17456248
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (n 27)
Study: 12841346
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (120 mg/day)
Study: 10543679
Drug: Sequential transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential transdermal progesterone with continuous transdermal oestrogen
Study: 31027120
Drug: Submucosal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal bupivacaine injection
Study: 22440906
Drug: Conventional solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional solution
Study: 27779568
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens (o‐CEE) 0.45 mg (n=230)
Study: 27779568
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (t‐E2) 50 μg (n=225)
Study: 19195512
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg orally twice daily)
Study: 10353511
Drug: Ceftriaxone, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 50 mg/kg (single intramuscular dose)
Study: 10353511
Drug: Amoxicillin/clavulanate, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate, 80 mg/kg/day of amoxicillin: 10 mg/kg/day of clavulanate for 10 days
Study: 1770473
Drug: Combined lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined lipid-lowering and antihypertensive treatment
Study: 29222893
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (KO) - 5 capsules (907 mg LC n-3 PUFA)
Study: 29222893
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) - 5 capsules (1441 mg LC n-3 PUFA)
Study: 22444237
Drug: Preoperative carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative carbohydrate treatment (PCT) - 600 ml of a carbohydrate-based drink (ONS, Fresenuis Kabi, 50 g carbohydrate, 15 g glutamine and antioxidants/300 ml)
Study: 22444237
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 600 ml of a carbohydrate-free drink (0 g carbohydrate)
Study: 27152748
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg IV-ibuprofen every 6 hours
Study: 17907107
Drug: Tesaglitazar 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesaglitazar 0.25 mg
Study: 17907109
Drug: Tesaglitazar 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesaglitazar 0.5 mg
Study: 17907108
Drug: Tesaglitazar 1
Normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesaglitazar 1 mg
Study: 17907107
Drug: Tesaglitazar (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesaglitazar (all doses)
Study: 10570375
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel pretreatment 3 times per week for 2 weeks
Study: 10570375
Drug: Thin application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin application of tazarotene gel immediately before phototherapy
Study: 10570375
Drug: Thick application
Normalized name: tick-borne encephalitis purified antigen Prefilled Syringe [Ticovac]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thick application of tazarotene gel immediately before phototherapy
Study: 23427393
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (Group A)
Study: 8635058
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (Group B)
Study: 2127226
Drug: N-acetylcysteine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (400 mg)
Study: 23530969
Drug: HQK-1001 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 (20 mg/kg per day)
Study: 16729930
Drug: Atorvastatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 80 mg daily
Study: 22085316
Drug: Rosuvastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin, 40 mg daily
Study: 19088267
Drug: AMG 487
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 487 at 25 mg
Study: 19088267
Drug: AMG 487
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 487 at higher doses (not specified)
Study: 18193495
Drug: Carraguard gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carraguard gel applied vaginally once per day for 14 days (women)
Study: 18193495
Drug: Carraguard gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carraguard gel applied directly to the penis once per day for 7 days (men)
Study: 11528360
Drug: Red clover
Normalized name: Red clover
DrugBank: Trifolium pratense pollen (DB15530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red clover isoflavones (approximately 50 mg)
Study: 2901993
Drug: Acrivastine (BW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrivastine (BW 825C; 8 mg 3 times daily)
Study: 2901993
Drug: Cyproheptadine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (4 mg 3 times daily)
Study: 26600645
Drug: Aqueous extract
Normalized name: green tea aqueous extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous extract of Hibiscus sabdariffa (150 mg/kg/day)
Study: 11468543
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg once daily)
Study: 26600645
Drug: Placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (150 mg/kg/day)
Study: 16644434
Drug: Increased preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased preload by rapid infusion of 30 mL/kg of saline over 15 minutes
Study: 12756423
Drug: Drug-herb interaction
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-herb interaction pairs involving herbal products and drugs
Study: 8701626
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg/die)
Study: 6430811
Drug: Molsidomine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (2 mg 4 times daily)
Study: 6430811
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (10 mg 4 times daily)
Study: 30395548
Drug: Daily Right
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Right Unilateral Ultrabrief ECT (RULUB)
Study: 27161974
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic treatment (n = 288)
Study: 21213495
Drug: Mefenamic acid,
Normalized name: Mefenamic Acid, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefenamic acid, 500 mg per oral three times a day for 5 days
Study: 11715356
Drug: Neutral endopeptidase
Normalized name: Neutral endopeptidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral endopeptidase inhibitors (in combination with ACE inhibitors)
Study: 11715356
Drug: Endothelin-1 antagonists
Normalized name: nitric oxide synthase endothelial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-1 antagonists
Study: 7626915
Drug: Inhaled bimakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bimakalim (cumulative doses of 10, 25, 40, and 100 micrograms, total cumulative dose 175 micrograms)
Study: 2510115
Drug: IgG Cutter
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG Cutter 0.6 mg per Kg BW per week
Study: 825821
Drug: Parenteral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral supplementation with dextrose and amino acids (67 cal/dl formula feeding)
Study: 825821
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding (100 cal/dl formula feeding)
Study: 825821
Drug: Parenteral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral supplementation
Study: 29049577
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention to reduce inappropriate antibiotic prescribing
Study: 26555159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of danoprevir (100 mg three times daily) and mericitabine (500 mg twice daily)
Study: 26555159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of danoprevir (600 mg twice daily) and mericitabine (1,000 mg twice daily)
Study: 26555159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mericitabine and ritonavir‐boosted danoprevir
Study: 19614805
Drug: T80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: T80 mg plus A10 mg
Study: 19614805
Drug: A10 mg
Normalized name: Antineoplaston A10
DrugBank: Antineoplaston A10 (DB11702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A10 mg
Study: 15173858
Drug: Epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90 mg m(‐2) plus Paclitaxel 200 mg m(‐2) (3‐h infusion) on day 1 every 3 weeks for eight courses (arm A)
Study: 15173858
Drug: Epirubicin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 120 mg m(‐2) on day 1 every 3 weeks for four courses followed by four courses of Paclitaxel 250 mg m(‐2) on day 1 every 3 weeks (arm B)
Study: 12473876
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (participants with antihypertensive drug treatment)
Study: 19174586
Drug: Noncontact, nonthermal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontact, nonthermal, low-frequency ultrasound therapy
Study: 16717032
Drug: Ximelagatran (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (2 x 36 mg)
Study: 12489490
Drug: Ximelagatran (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (2 x 24 mg daily)
Study: 12489490
Drug: Subcutaneous LMW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous LMW heparin followed by warfarin
Study: 30286851
Drug: Oxycodone (OXY)
Normalized name: oxycodone hydrochloride Oral Tablet [M-Oxy]
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone (OXY) 5 mg
Study: 30286851
Drug: Ibuprofen (IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBU) 600 mg
Study: 30286851
Drug: Acetaminophen (ACE)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (ACE) 500 mg
Study: 30810754
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-opioid medications)
Study: 28750677
Drug: Inhaled AP301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled AP301
Study: 26378637
Drug: Aldoxorubicin 350
Normalized name: Aldoxorubicin
DrugBank: Aldoxorubicin (DB06013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldoxorubicin 350 mg/m2
Study: 26378637
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m2
Study: 23514733
Drug: LY2189102 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2189102 0.6 mg
Study: 23514733
Drug: LY2189102 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2189102 18 mg
Study: 23514733
Drug: LY2189102 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2189102 180 mg
Study: 14504122
Drug: 1-day quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day quadruple therapy (4-drug regimen)
Study: 14504122
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy (3-drug regimen)
Study: 10802469
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine infusion at 2 mL per hour
Study: 10802469
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion at 2 mL per hour
Study: 8874303
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg, maximum dose 10 mg)
Study: 6298318
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir applied six times daily for five days
Study: 26242184
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist (GLP-1RA) therapy
Study: 17074146
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (aspirin, clopidogrel, cilostazol)
Study: 29273207
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (aspirin, clopidogrel, placebo)
Study: 28329061
Drug: Peginterferon add-on
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon add-on therapy (n = 39)
Study: 28329061
Drug: NA monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA monotherapy (n = 38)
Study: 28329061
Drug: Peginterferon add-on
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon add-on therapy (among 58 interferon-naive patients)
Study: 28329061
Drug: NA monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA monotherapy (among 58 interferon-naive patients)
Study: 28329061
Drug: Responders at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders at week 48 who discontinued NA therapy at week 72 (n = 8)
Study: 28329061
Drug: Add-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on therapy group (n = 6)
Study: 28329061
Drug: Monotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy group (n = 2)
Study: 21215350
Drug: CB‐CIK +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB‐CIK + Chemotherapy
Study: 18792997
Drug: Ultrasound-guided extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided extracorporeal shock wave therapy (ESWT)
Study: 18792997
Drug: Subtherapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtherapeutic dose treatment
Study: 16421419
Drug: FOLFOX4 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 administered every 2 weeks until progression (arm A)
Study: 8324432
Drug: Multivitamin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplementation (0.8 mg of folic acid)
Study: 8324432
Drug: Trace elements
Normalized name: trace elements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trace elements supplement
Study: 18824608
Drug: BILR 355
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILR 355 alone (12.5 mg to 100 mg)
Study: 18824608
Drug: BILR 355
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILR 355 with ritonavir (RTV) (5 mg to 87.5 mg)
Study: 19116439
Drug: Medicine-ball chest
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine-ball chest passes
Study: 1517839
Drug: 131I‐chimeric B72.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I‐chimeric B72.3 (IgG‐4) at total doses of 28 or 36 mCi/m2 in two or three weekly fractions
Study: 1517839
Drug: 131I‐chimeric B72.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I‐chimeric B72.3 (IgG‐4) at total doses of 36 mCi/m2
Study: 1517839
Drug: Second course
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second course of therapy with 131I‐chimeric B72.3 (IgG‐4)
Study: 1517839
Drug: Dose fractionation
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose fractionation of 131I‐chimeric B72.3 (IgG‐4)
Study: 6468471
Drug: SUR 2647
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUR 2647 combination (2 sachets b.i.d. on the day of operation, 1 sachet b.i.d. for the following two days)
Study: 6468471
Drug: Paracetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (2 tablets q.i.d. on the day of operation, 1 tablet q.i.d. for the following two days)
Study: 30417227
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 0.015 mg/ml epinephrine (Group A)
Study: 30417227
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 0.015 mg/ml epinephrine (Group B)
Study: 30417227
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine with 0.012 mg/ml epinephrine (Group C)
Study: 25676674
Drug: Lansoprazole OD
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole OD 30 mg from a nasogastric tube for 14 days
Study: 20040336
Drug: Bezafibrate (BF)
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (BF) administration
Study: 8826310
Drug: Automated medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated medication distribution systems